Ad
related to: high dose brachytherapy prostate cancer treatment
Search results
Results From The WOW.Com Content Network
Brachytherapy is a type of radiotherapy, or radiation treatment, offered to certain cancer patients. There are two types of brachytherapy – high dose-rate (HDR) and low dose-rate (LDR). LDR brachytherapy is the one most commonly used to treat prostate cancer. It may be referred to as 'seed implantation' or it may be called 'pinhole surgery'. [1]
Body sites in which brachytherapy can be used to treat cancer. Brachytherapy is commonly used to treat cancers of the cervix, prostate, breast, and skin. [1]Brachytherapy can also be used in the treatment of tumours of the brain, eye, head and neck region (lip, floor of mouth, tongue, nasopharynx and oropharynx), [10] respiratory tract (trachea and bronchi), digestive tract (oesophagus, gall ...
Treatment for prostate cancer may involve active surveillance, surgery, radiation therapy – including brachytherapy (prostate brachytherapy) and external-beam radiation therapy, proton therapy, high-intensity focused ultrasound (HIFU), cryosurgery, hormonal therapy, chemotherapy, or some combination. Treatments also extend to survivorship ...
Brachytherapy is delivered by placing radiation source(s) inside or next to the area requiring treatment. Brachytherapy is commonly used as an effective treatment for cervical, [106] prostate, [107] breast, [108] and skin cancer [109] and can also be used to treat tumors in many other body sites. [110]
In radiotherapy, radiation treatment planning (RTP) is the process in which a team consisting of radiation oncologists, radiation therapist, medical physicists and medical dosimetrists plan the appropriate external beam radiotherapy or internal brachytherapy treatment technique for a patient with cancer.
One of the recent methods in radiation therapy related to cancer care is called HDR (High Dose Rate) internal brachytherapy. Prior to HDR, LDR (Low Dose Rate) brachytherapy was commonly in use for prostate cancer. Chief urologist of Docrates, Dr. Martti Ala-Opas, was the first one in Finland who utilized LDR brachytherapy for prostate cancer.
Iodine-125 (125 I) is a radioisotope of iodine which has uses in biological assays, nuclear medicine imaging and in radiation therapy as brachytherapy to treat a number of conditions, including prostate cancer, uveal melanomas, and brain tumors. It is the second longest-lived radioisotope of iodine, after iodine-129.
One trial [2] for prostate cancer ran in 2011. [1] In 2016 the HYPRO study reported results comparing the use of standard fractionation (39 fractions of 2 Gy for 8 weeks) with hypofractionation (with 19 fractions of 3.4 Gy for 6.5 weeks) among 820 patients with intermediate- or high-risk prostate cancer.